Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
This time, the activity dropped and recovered as expected, but to a new, lower baseline set by ketamine ... However, until now, it wasn't fully understood how the drug produced its antidepressant ...
"The esketamine benefits without an antidepressant give patients and ... announced in July the submission of a supplemental new drug application to the FDA seeking approval for esketamine as ...
Although significant advances have been made in the treatment of depressive disorders during the last decades, there are still unmet therapeutic needs in patients diagnosed with this type of pathology ...
Opens in a new tab or window Share on X ... total score change from baseline was -2.6 with the study drug plus current antidepressant treatment compared with placebo (95% CI -4.53 to -0.74 ...